Kwality Pharmaceuticals (539997) investor relations material

Executive summary

• Five operational manufacturing units with a sixth hormone facility to commence by November 2026; strong focus on expanding product registrations and global reach.

• Achieved Q1 FY27 revenue of INR 162 crore and net profit of INR 26 crore, reflecting strong YoY and QoQ growth.

• FY 2027 revenue guidance raised to over INR 700 crore (39% YoY growth), with EBITDA margin of 27%-28% and PAT margin of 15.5%+.

• Ongoing investments in bioequivalence (BE) programs, biosimilars, and complex injectables to drive future growth.

• Focused on high-margin critical care, biosimilars, and oncology molecules for future growth.

Financial highlights

• Q1 FY27 revenue grew 46% YoY to INR 162 crore, with EBITDA margin at 25.3% and PAT up 119% YoY to INR 26 crore.

• Gross margin for the quarter at 53%, down from 56%-57% sequentially; expected to stabilize at 47%-51% as product mix evolves.

• Receivables cycle improved to 165-170 days from 208 days, with further improvement targeted.

• FY26 revenue was INR 503 crore, with PAT at INR 67 crore; PAT growth outpaced revenue growth by ~3x.

• Working capital cycle improved from 297 to 161 days over three years.

Outlook and guidance

• FY 2027 revenue expected to surpass INR 700 crore, with EBITDA margin guidance of 27%-28% and PAT margin of 15.5%+.

• Year-on-year revenue growth of 25%-30% projected through FY 2030, targeting INR 1,500 crore.

• FY29 revenue milestone set at INR 1,000+ crore, with target EBITDA margin of 30%+.

• Hormone and biological facility revenues not included in near-term guidance; significant upside possible if registrations are timely.

• BE program expected to generate INR 80-100 crore in FY 2028 and INR 400-500 crore by FY 2029.